6nmb: Difference between revisions

Line 1:

~~'''Unreleased structure'''~~

The ~~entry 6nmb~~ is ~~ON HOLD~~ ~~until Paper Publication~~

==Tranexamic Acid is an Active Site Inhibitor of Urokinase Plasminogen Activator==

~~Authors~~:

== Structural highlights ==

<table><tr><td colspan='2'>[[6nmb]] is a 4 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6NMB OCA]. For a guided tour on the structure components use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6NMB FirstGlance].

~~Description~~:

</td></tr><tr id='ligand'><td class="sblockLbl">[[Ligand|Ligands:]]</td><td class="sblockDat"><scene name='pdbligand=AMH:TRANS-4-AMINOMETHYLCYCLOHEXANE-1-CARBOXYLIC+ACID'>AMH</scene>, <scene name='pdbligand=NO3:NITRATE+ION'>NO3</scene></td></tr>

[[Category: ~~Unreleased Structures~~]]

<tr id='activity'><td class="sblockLbl">Activity:</td><td class="sblockDat">[http://en.wikipedia.org/wiki/U-plasminogen_activator U-plasminogen activator], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=3.4.21.73 3.4.21.73] </td></tr>

<tr id='resources'><td class="sblockLbl">Resources:</td><td class="sblockDat">[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6nmb FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6nmb OCA], [http://pdbe.org/6nmb PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6nmb RCSB], [http://www.ebi.ac.uk/pdbsum/6nmb PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6nmb ProSAT]</td></tr>

</table>

== Disease ==

[[http://www.uniprot.org/uniprot/UROK_HUMAN UROK_HUMAN]] Defects in PLAU are the cause of Quebec platelet disorder (QPD) [MIM:[http://omim.org/entry/601709 601709]]. QPD is an autosomal dominant bleeding disorder due to a gain-of-function defect in fibrinolysis. Although affected individuals do not exhibit systemic fibrinolysis, they show delayed onset bleeding after challenge, such as surgery. The hallmark of the disorder is markedly increased PLAU levels within platelets, which causes intraplatelet plasmin generation and secondary degradation of alpha-granule proteins.<ref>PMID:20007542</ref>

== Function ==

[[http://www.uniprot.org/uniprot/UROK_HUMAN UROK_HUMAN]] Specifically cleaves the zymogen plasminogen to form the active enzyme plasmin.

== References ==

__TOC__

</StructureSection>

[[Category: U-plasminogen activator]]

[[Category: Law, R H.P]]

[[Category: Wu, G]]

[[Category: Fibrinolysis]]

[[Category: Hydrolase]]

[[Category: Inhibitor]]

[[Category: Serine protease]]

Navigation menu

Page actions

Page actions

Personal tools

Navigation

Search

Tools

@@ Line 1: / Line 1: @@
-'''Unreleased structure'''
-The entry 6nmb is ON HOLD  until Paper Publication
+==Tranexamic Acid is an Active Site Inhibitor of Urokinase Plasminogen Activator==
+<StructureSection load='6nmb' size='340' side='right'  caption='[[6nmb]], [[Resolution|resolution]] 2.30&Aring;' scene=''>
-Authors:
+== Structural highlights ==
+<table><tr><td colspan='2'>[[6nmb]] is a 4 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6NMB OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6NMB FirstGlance]. <br>
-Description:
+</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=AMH:TRANS-4-AMINOMETHYLCYCLOHEXANE-1-CARBOXYLIC+ACID'>AMH</scene>, <scene name='pdbligand=NO3:NITRATE+ION'>NO3</scene></td></tr>
-[[Category: Unreleased Structures]]
+<tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/U-plasminogen_activator U-plasminogen activator], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=3.4.21.73 3.4.21.73] </span></td></tr>
+<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6nmb FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6nmb OCA], [http://pdbe.org/6nmb PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6nmb RCSB], [http://www.ebi.ac.uk/pdbsum/6nmb PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6nmb ProSAT]</span></td></tr>
+</table>
+== Disease ==
+[[http://www.uniprot.org/uniprot/UROK_HUMAN UROK_HUMAN]] Defects in PLAU are the cause of Quebec platelet disorder (QPD) [MIM:[http://omim.org/entry/601709 601709]]. QPD is an autosomal dominant bleeding disorder due to a gain-of-function defect in fibrinolysis. Although affected individuals do not exhibit systemic fibrinolysis, they show delayed onset bleeding after challenge, such as surgery. The hallmark of the disorder is markedly increased PLAU levels within platelets, which causes intraplatelet plasmin generation and secondary degradation of alpha-granule proteins.<ref>PMID:20007542</ref>
+== Function ==
+[[http://www.uniprot.org/uniprot/UROK_HUMAN UROK_HUMAN]] Specifically cleaves the zymogen plasminogen to form the active enzyme plasmin.
+== References ==
+<references/>
+__TOC__
+</StructureSection>
+[[Category: U-plasminogen activator]]
+[[Category: Law, R H.P]]
+[[Category: Wu, G]]
+[[Category: Fibrinolysis]]
+[[Category: Hydrolase]]
+[[Category: Inhibitor]]
+[[Category: Serine protease]]